EP1499204A2 - Physiologically compatible, phospholipid-containing, stable and hard matrix - Google Patents
Physiologically compatible, phospholipid-containing, stable and hard matrixInfo
- Publication number
- EP1499204A2 EP1499204A2 EP03718771A EP03718771A EP1499204A2 EP 1499204 A2 EP1499204 A2 EP 1499204A2 EP 03718771 A EP03718771 A EP 03718771A EP 03718771 A EP03718771 A EP 03718771A EP 1499204 A2 EP1499204 A2 EP 1499204A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- matrix
- matrix according
- weight
- proteins
- phospholipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000011159 matrix material Substances 0.000 title claims abstract description 60
- 150000003904 phospholipids Chemical class 0.000 title claims abstract description 48
- 230000000975 bioactive effect Effects 0.000 claims abstract description 30
- 239000000126 substance Substances 0.000 claims abstract description 16
- 239000000470 constituent Substances 0.000 claims abstract description 9
- 235000018102 proteins Nutrition 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 9
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 8
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 8
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 7
- 239000007858 starting material Substances 0.000 claims abstract description 6
- 239000000463 material Substances 0.000 claims abstract description 5
- 239000011573 trace mineral Substances 0.000 claims abstract description 5
- 235000013619 trace mineral Nutrition 0.000 claims abstract description 5
- 235000001014 amino acid Nutrition 0.000 claims abstract description 4
- 150000001413 amino acids Chemical class 0.000 claims abstract description 4
- 235000013376 functional food Nutrition 0.000 claims abstract description 4
- 229930003231 vitamin Natural products 0.000 claims abstract description 4
- 229940088594 vitamin Drugs 0.000 claims abstract description 4
- 235000013343 vitamin Nutrition 0.000 claims abstract description 4
- 239000011782 vitamin Substances 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 239000012876 carrier material Substances 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- 239000003094 microcapsule Substances 0.000 claims description 11
- 150000002632 lipids Chemical class 0.000 claims description 8
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 6
- 150000003626 triacylglycerols Chemical class 0.000 claims description 6
- 229960005150 glycerol Drugs 0.000 claims description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 4
- 229960001231 choline Drugs 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 4
- 229960000367 inositol Drugs 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- 229920000881 Modified starch Polymers 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 150000002016 disaccharides Chemical class 0.000 claims description 3
- 229940031098 ethanolamine Drugs 0.000 claims description 3
- 150000002772 monosaccharides Chemical class 0.000 claims description 3
- 229960001153 serine Drugs 0.000 claims description 3
- 235000013311 vegetables Nutrition 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- 102000011632 Caseins Human genes 0.000 claims description 2
- 108010076119 Caseins Proteins 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 108010068370 Glutens Proteins 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 229920002494 Zein Polymers 0.000 claims description 2
- 108010055615 Zein Proteins 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 2
- 235000021240 caseins Nutrition 0.000 claims description 2
- 229940021722 caseins Drugs 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 2
- 230000003111 delayed effect Effects 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000021312 gluten Nutrition 0.000 claims description 2
- 239000000416 hydrocolloid Substances 0.000 claims description 2
- 230000003340 mental effect Effects 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 235000010755 mineral Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 2
- 235000013824 polyphenols Nutrition 0.000 claims description 2
- 150000004760 silicates Chemical class 0.000 claims description 2
- 108010027322 single cell proteins Proteins 0.000 claims description 2
- 150000005846 sugar alcohols Chemical class 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000021119 whey protein Nutrition 0.000 claims description 2
- 229940093612 zein Drugs 0.000 claims description 2
- 239000005019 zein Substances 0.000 claims description 2
- 108010073771 Soybean Proteins Proteins 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940001941 soy protein Drugs 0.000 claims 1
- 238000005728 strengthening Methods 0.000 claims 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 abstract description 17
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 abstract description 17
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract description 9
- 239000004615 ingredient Substances 0.000 abstract description 3
- 239000002253 acid Substances 0.000 description 10
- 239000000787 lecithin Substances 0.000 description 10
- 235000010445 lecithin Nutrition 0.000 description 10
- 235000019871 vegetable fat Nutrition 0.000 description 9
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 7
- 229940067606 lecithin Drugs 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 229930186217 Glycolipid Natural products 0.000 description 4
- 235000021314 Palmitic acid Nutrition 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 229960004488 linolenic acid Drugs 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- -1 however Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- IJTNSXPMYKJZPR-UHFFFAOYSA-N parinaric acid Chemical compound CCC=CC=CC=CC=CCCCCCCCC(O)=O IJTNSXPMYKJZPR-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- GWHCXVQVJPWHRF-KTKRTIGZSA-N (15Z)-tetracosenoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-KTKRTIGZSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 108091065810 E family Proteins 0.000 description 1
- URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
- SNVFDPHQAOXWJZ-UHFFFAOYSA-N Furcelleran Chemical compound CCOC(=O)C1=C(C)NC(C=2C=CC=CC=2)=C(C(=O)OCC=2C=CC=CC=2)C1C#CC1=CC=CC=C1 SNVFDPHQAOXWJZ-UHFFFAOYSA-N 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 235000021353 Lignoceric acid Nutrition 0.000 description 1
- CQXMAMUUWHYSIY-UHFFFAOYSA-N Lignoceric acid Natural products CCCCCCCCCCCCCCCCCCCCCCCC(=O)OCCC1=CC=C(O)C=C1 CQXMAMUUWHYSIY-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- XJXROGWVRIJYMO-SJDLZYGOSA-N Nervonic acid Natural products O=C(O)[C@@H](/C=C/CCCCCCCC)CCCCCCCCCCCC XJXROGWVRIJYMO-SJDLZYGOSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- IJTNSXPMYKJZPR-WVRBZULHSA-N alpha-parinaric acid Natural products CCC=C/C=C/C=C/C=CCCCCCCCC(=O)O IJTNSXPMYKJZPR-WVRBZULHSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 239000010480 babassu oil Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- GWHCXVQVJPWHRF-UHFFFAOYSA-N cis-tetracosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCCCCCC(O)=O GWHCXVQVJPWHRF-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- MAMJNXVNGGBHFN-UHFFFAOYSA-N docosa-1,3,5,7,9,11-hexaene Chemical compound CCCCCCCCCCC=CC=CC=CC=CC=CC=C MAMJNXVNGGBHFN-UHFFFAOYSA-N 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- FARYTWBWLZAXNK-WAYWQWQTSA-N ethyl (z)-3-(methylamino)but-2-enoate Chemical compound CCOC(=O)\C=C(\C)NC FARYTWBWLZAXNK-WAYWQWQTSA-N 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011868 grain product Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 229940116364 hard fat Drugs 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000036997 mental performance Effects 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229960002969 oleic acid Drugs 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 150000002896 organic halogen compounds Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000019809 paraffin wax Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000036314 physical performance Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229940068065 phytosterols Drugs 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000004170 rice bran wax Substances 0.000 description 1
- 235000019384 rice bran wax Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 239000012176 shellac wax Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical group CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 229940068778 tocotrienols Drugs 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000005457 triglyceride group Chemical group 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
- A23P10/35—Encapsulation of particles, e.g. foodstuff additives with oils, lipids, monoglycerides or diglycerides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a physiologically compatible, stable and hard matrix containing phospholipids, in particular a microcapsule consisting of a carrier material and a bioactive component.
- the substance class of the phospholipids are so-called complex lipids with amphiphilic, ie at the same time lipophilic and hydrophilic properties, which among other things enables them to form lipid bilayers in aqueous media.
- phospholipids are phosphodiesters in which the phosphoric acid is esterified on the one hand with a sphingosine or glyceride residue and on the other hand with choline, ethanolamine, serine, inositol or glycerol.
- Phosphatidylcholine is also known as lecithin and is also the eponym for a large group of special phospholipids, the lecithins.
- Phosphatidylserine and phosphatidylethanolamine are also known as cephalins.
- the lyso derivatives which also belong to this group, are formed by hydrolytic cleavage using specific phospholipases.
- Phospholipids are typically not soluble in acetone, which is why they are also called acetone-insoluble phosphatides or acetone-insoluble substances.
- Lecithins are mixtures or fractions of phosphatides that are obtained from animal or vegetable foods using physical methods; Lecithins contain at least 60% of substances insoluble in acetone. Because of this feature, lecithin containing products are checked for their actual phosphatide or phospholipid content using the so-called acetone solubility test.
- Capsules containing phospholipids are well known from the prior art and mostly contain phospholipids as the coating substance. If phospholipids are used in the filling, i.e. in the capsule core, they mostly act in small proportions there as formulation aids with mostly solubilizing properties.
- the phospholipids Due to their amphiphilic properties, the phospholipids also serve as coating substances for the known liposomes and transferosomes. In this context, they are used primarily because of their bioadhesive characteristics in the area of mucosal applications, whereby they are particularly introduced into the nasal and oral cavities.
- phospholipids are also used as surface-active formulation aids (surfactants).
- lysophospholipids are described as solubilizers for hydrophobic bioactive substances.
- PS phosphatidylserine
- the object of the prior art is therefore to provide a physiologically compatible, phospholipid-containing stable and solid matrix consisting of a carrier material and a bioactive component which, on the one hand, has the proportions of the phospholipid based on the starting material contains that go beyond the known amounts in which phospholipids are used as a coating or formulation aid, and thus contain amounts of phospholipid that can be used, for example, as a food supplement.
- the matrix should have a size that allows easy and pleasant intake, but at the same time is sufficient to take up an amount of phospholipid sufficient for a physiological effect.
- This object was achieved with a corresponding matrix which has a total diameter between 0.1 and 5000 ⁇ m and which, as a bioactive component, is> 5% by weight, preferably> 10% by weight and in particular> 20% by weight, based on the Contains starting material of acetone-insoluble phospholipid components.
- this matrix according to the invention that compliance can be significantly increased in accordance with the task, since the small matrix size makes it easier to take and above all does not negatively influence the feeling of swallowing.
- amounts of phospholipid with bioactive activity can be accommodated in the matrix according to the invention, which allow a better dosage of the daily amount.
- the matrix offers the advantage that it can be produced in numerous variants depending on the respective manufacturing process and with regard to the look, feel and taste. These advantages could not have been foreseen.
- the term “matrix” is defined as the entirety of the carrier material and the bioactive component, the bioactive component being distributed homogeneously or heterogeneously in the carrier material or the carrier material being able to at least partially encase the bioactive component; however, the bioactive component can also be applied to the carrier material. Mixed forms of these variants are of course also possible.
- hard defines the physical state of the claimed matrix in the sense of not being soft and includes all states that are in harmony with it and are independent of the external shape, such as pellets, granules, hard capsules, etc. Soft gelatin capsules therefore expressly fall outside this definition , Amorphous, plastic manifestations of hard consistency, but fulfill the conditions of a hard matrix.
- bioactive is to be understood as meaning the effect of the phospholipids in such a way that they have a biological effect in the living organism during or after their release from the capsule in the absorption area, on the transport route or at the destination, which is usually pharmaceutical Preparations in the human and veterinary field apply.
- a matrix which contains between 5 and 90% by weight and in particular between 20 and 80% by weight, based on the starting material, of acetone-insoluble phospholipid constituents, fractions being particularly preferred which are between 40 and 70% by weight.
- Phosphatidylserine, choline, ethanolamine, inositol, glycerol, their lyso compounds and / or their derivatives are preferred acetone-insoluble constituents for the purposes of the present invention.
- these compounds each preferably contain a residue at position sn-1 or sn-2, which is derived from a C 2 -C 30 -carboxylic acid bonded to the hydroxyl groups of glycerol, in particular a C 12 -C 28 carboxylic acid.
- the acid residues can be linear or branched, saturated or mono- or polyunsaturated.
- residues which are caused by the binding of acetic acid, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, arachic acid, behenic acid, lignoceric acid, linolenic acid, eicosapentaenoic acid, erucic acid, nervonic acid, a- or? -Earic acid or parinaric acid are formed.
- Residues formed by binding palmitic acid, stearic acid, oleic acid, linoleic acid, ⁇ -linolenic acid, arachidonic acid or docosahexaenoic acid are particularly preferred.
- the acid residues bound to the two OH groups of the glycerol still available can be the same or different.
- sphingophospholipids in particular, and preferably sphingomyelin and its derivatives, have been found to be suitable.
- modified carbohydrates and proteins, hydrophobic materials such as waxes, triglycerides, lipids and polymers or mineral components such as silicates and their mixtures have proven to be particularly suitable as “hard” carrier materials.
- the lipids can be hydrogenated or have a special composition; the polymers can be pharmaceutical and / or food-grade polymers.
- cereal products from corn, wheat, oats, rice, etc. which are typical hard carrier materials as flakes or extrudates.
- the invention provides that, as representatives of the carbohydrates, in particular starch (derivatives), mono- and disaccharides and their sugar alcohols, glucose syrup, dextrins and hydrocolloids, such as e.g. Algatin, pectins, chitosan and cellulose (derivatives) can be used.
- starch derivatives
- mono- and disaccharides and their sugar alcohols glucose syrup
- dextrins and hydrocolloids such as e.g. Algatin, pectins, chitosan and cellulose (derivatives)
- Vegetable, animal or microbial proteins such as e.g. Zein, gluten, gelatin, caseins, whey proteins, as well as single-cell proteins, textured proteins such as spun or extruded (soy) protein isolate or mixtures thereof.
- the respective special representatives can of course be extended by other suitable carrier materials, in particular as carbohydrates maltodextrins, sucrose, mono- and disaccharides and their alcohols, modified starches (eg esters and ethers), gum acacia, xanthan gum, gum arabic, carrageenan, Furcelleran, agar, alginates, tragacanth and carboxymethyl cellulose are recommended.
- suitable carrier materials in particular as carbohydrates maltodextrins, sucrose, mono- and disaccharides and their alcohols, modified starches (eg esters and ethers), gum acacia, xanthan gum, gum arabic, carrageenan, Furcelleran, agar, alginates, tragacanth and carboxymethyl cellulose are recommended.
- hydrogenated vegetable oils can also be used on hydrophobic materials; but also natural oils, such as palm oil, cottonseed oil, soybean oil, corn oil, palm kernel oil, babassu oil, sunflower oil and safflower oil can also be used, which can also be used with beeswax, petroleum-based paraffin wax, rice bran wax, castor wax, cardellita wax, carnauba wax, shellac and microcrystalline wax can be mixed.
- Tristearins, stearic acid and fats are recommended as further representatives of the lipids, although the phospholipids themselves can of course also be chosen as the coating or their constituent in accordance with the prior art.
- the range that the carrier material can cover is just as wide as the proportion of the bioactive component. Proportions of ⁇ 95% by weight and in particular those between 30 and 80% by weight, based on the total matrix weight, have proven useful in this regard.
- the proportion of carrier material in the matrix is preferably> 5% by weight, in particular 10% by weight, more preferably> 20% by weight, even more preferably> 40% by weight and most preferably ⁇ 50% by weight.
- the matrix can of course also contain other bioactive substances such as amino acids, vitamins, polyphenols, carbohydrates, lipids, trace elements and minerals and their suitable derivatives contain.
- bioactive substances such as amino acids, vitamins, polyphenols, carbohydrates, lipids, trace elements and minerals and their suitable derivatives contain.
- the essential amino acids come into question, but also, for example, creatine and other special amino acids such as theanine and their derivatives;
- the representatives of the vitamins are primarily the fat-soluble ones, such as the vitamin E family, the tocotrienols, phytosterols and other bioactive fat accompanying substances, as well as representatives of the vitamin D series or vitamin C that deviate from the phospholipids.
- bioactive substances can be added to the carrier material, the bioactive component or both.
- particularly suitable as carrier materials are substances which enable complete encapsulation to be achieved, and substances which provide a matrix with high stability and low shear stress.
- Essential to the invention for the claimed matrix is, among other things, its special diameter, which, in addition to its hard state, distinguishes it, among other things, from the known larger soft gelatin capsules.
- diameters of the total matrix that lie between 10 ⁇ m and 1000 ⁇ m and in particular between 50 and 500 ⁇ m are to be regarded as preferred.
- the claimed matrix is not restricted to a special shape and, consequently, it can be spherical, rounded or irregular in shape.
- spherical or lenticular forms have been shown to be particularly suitable, although of course all other shape variants, such as cylinders, pillows, amorphous states (e.g. flakes) and the like, depending on the application, can of course always consist of the carrier material and the bioactive one Component.
- the invention preferably provides for the matrix content to have a liquid consistency, which of course then necessitates a generally rigid and hard coating.
- Matrix variants in the form of a microcapsule have been shown to be particularly suitable, which the present invention also takes into account.
- the present invention also claims its use in functional foods, special foods and dietary supplements, with particular emphasis on the delayed release of the bioactive component.
- the sustained release effect does not exclude that the complete matrix or its components (carrier material, bioactive component) can be attacked by the gastric juices or that they are subject to chemical and / or enzymatic influences in the GI tract.
- the preferred use for the claimed matrix is to prevent increased serum cholesterol levels and (a) typical diabetes symptoms, as well as to strengthen mental fitness, physical resilience and physical and mental performance.
- the claimed matrix represents a particularly suitable dosage form, since it can be produced in numerous forms and flavors and can therefore be added to solid, semi-solid and liquid foods without problems and with high inherent stability ,
- the most suitable dosage form is direct oral intake.
- the following examples underline the advantages of the physiologically compatible phospholipid-containing, stable and hard matrix according to the invention.
- Example 1 Microcapsule with 8% by weight phosphatidylserine
- phosphatidylserine (LeciPS ' s 20F from Degussa BioActives GmbH), consisting of a mixture of triglycerides, phospholipids and glycolipids, with a natural, vegetable fat in
- the natural, vegetable fat was characterized by the following characteristics: melting point about 55 ° C, peroxide number max. 2 meq O / kg, acid number max. 1 mg KOH / g, iodine number max. 5 gl / 100 g, saponification number 185-215 mg KOH / g, more than 94% of the natural acids (approx. 33% palmitic acid, approx. 60% stearic acid) are saturated.
- the spherical matrix obtained in this way in the form of microcapsules had an average overall diameter of 100 to 250 // m and the following composition:
- phosphatidylserine 55% by weight of vegetable fat and 37% by weight of a mixture of triglycerides, glycolipids and other phospholipids.
- Table 1 shows for the very hydrolysis-sensitive phosphatidylserine that embedding the phospholipids in the matrix according to the invention effects, among other things, a stabilizing effect against hydrolysis.
- Microcapsule with 14% by weight phosphatidylcholine Using the known "spray technology", a 35% by weight solution of phosphatidylcholine (Epikuron ® 1 35F from Degussa BioActives GmbH) consisting of a mixture of triglycerides, phospholipids and glycolipids with a natural, encapsulated vegetable fat
- phosphatidylcholine Epikuron ® 1 35F from Degussa BioActives GmbH
- the spherical matrix thus obtained in the form of microcapsules had an average overall diameter of 1 00 to 250 ⁇ m and the following composition: 14% by weight phosphatidylcholine, 46% by weight vegetable fat and 40% by weight
- % of a mixture of triglycerides, glycolipids and other phospholipids % of a mixture of triglycerides, glycolipids and other phospholipids.
- Table 1 shows that embedding the phospholipids in the matrix according to the invention has, inter alia, a stabilizing effect against hydrolysis.
- the natural, vegetable fat was characterized by the following characteristics:
- the spherical matrix thus obtained in the form of microcapsules had an average overall diameter of 1 00 to 250 ⁇ m and the following composition:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a physiologically compatible, phospholipid-containing, stable and hard matrix, comprised of a supporting material and of a bioactive constituent, which has an overall diameter ranging from 0.1 to 5000 µm and which contains, as bioactive constituents, = 5 wt. %, with regard to the starting material, of acetone-insoluble phospholipid constituents that, in particular, are phosphatidylserine, phosphatidylcholine and the like, as well as lyso variants and/or derivatives thereof. This matrix together with a preferred supporting material comprised of carbohydrates and/or of proteins and, preferably, of additional bioactive substances provided in the form of ingredients such as amino acids, vitamins, trace elements and the like can have a liquid content and is used, in particular, in functional foods, special foods and food supplements.
Description
Physiologisch verträgliche, Phospholipid-haltige, stabile und harte MatrixPhysiologically compatible, stable and hard matrix containing phospholipids
Beschreibungdescription
Gegenstand der vorliegenden Erfindung ist eine physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix, insbesondere eine Mikrokap- sel bestehend aus einem Trägermaterial und einer bioaktiven Komponente.The present invention relates to a physiologically compatible, stable and hard matrix containing phospholipids, in particular a microcapsule consisting of a carrier material and a bioactive component.
Bei der Substanzklasse der Phospholipide handelt es sich um sogenannte komplexe Lipide mit amphiphilen, also gleichzeitig lipophilen und hydrophilen Eigenschaften, was sie unter anderem zur Ausbildung von Lipid-Doppel- schichten in wässrigen Medien befähigt.The substance class of the phospholipids are so-called complex lipids with amphiphilic, ie at the same time lipophilic and hydrophilic properties, which among other things enables them to form lipid bilayers in aqueous media.
Phospholipide (auch Phosphatide genannt) sind chemisch betrachtet Phos- phodiester, bei denen die Phosphorsäure einerseits mit einem Sphingosin- oder Glyceridrest und andererseits mit Cholin, Ethanolamin, Serin, Inosit oder Glycerin verestert ist. Das Phosphatidylcholin ist auch als Lecithin bekannt und ist zugleich Namensgeber für eine große Gruppe spezieller Phospholipide, die Lecithine. Phosphatidylserin und Phosphatidylethanol- amin werden auch als Kephaline bezeichnet.From a chemical point of view, phospholipids (also called phosphatides) are phosphodiesters in which the phosphoric acid is esterified on the one hand with a sphingosine or glyceride residue and on the other hand with choline, ethanolamine, serine, inositol or glycerol. Phosphatidylcholine is also known as lecithin and is also the eponym for a large group of special phospholipids, the lecithins. Phosphatidylserine and phosphatidylethanolamine are also known as cephalins.
Die ebenfalls zu dieser Gruppe gehörenden Lyso-Derivate entstehen durch hydrolytische Spaltung mittels spezifischer Phospholipasen.The lyso derivatives, which also belong to this group, are formed by hydrolytic cleavage using specific phospholipases.
Phospholipide sind typischerweise in Aceton nicht löslich, weshalb man sie auch als Aceton-unlösliche Phosphatide oder Aceton-unlösliche Stoffe bezeichnet. Lecithine sind Mischungen oder Fraktionen aus Phosphatiden, die mittels physikalischer Verfahren aus tierischen oder pflanzlichen Nahrungsmitteln gewonnen werden; Lecithine enthalten mindestens 60 % in Aceton unlöslicher Stoffe. Aufgrund dieses Merkmals können Lecithin-
haltige Produkte mit Hilfe des sogenannten Aceton-Löslichkeitstests auf deren tatsächlichen Phosphatid- oder Phospholipid-Gehalt geprüft werden.Phospholipids are typically not soluble in acetone, which is why they are also called acetone-insoluble phosphatides or acetone-insoluble substances. Lecithins are mixtures or fractions of phosphatides that are obtained from animal or vegetable foods using physical methods; Lecithins contain at least 60% of substances insoluble in acetone. Because of this feature, lecithin containing products are checked for their actual phosphatide or phospholipid content using the so-called acetone solubility test.
Phospholipid-haltige Kapseln sind aus dem Stand der Technik hinlänglich bekannt und enthalten Phospholipide zumeist als Hüllsubstanz. Werden Phospholipide in der Füllung, also im Kapselkern eingesetzt, so fungieren sie dort zumeist in geringen Anteilen als Formulierungs-Hilfsmittel mit meist lösungsvermittelnden Eigenschaften.Capsules containing phospholipids are well known from the prior art and mostly contain phospholipids as the coating substance. If phospholipids are used in the filling, i.e. in the capsule core, they mostly act in small proportions there as formulation aids with mostly solubilizing properties.
Aufgrund ihrer amphiphilen Eigenschaften dienen die Phospholipide auch als Hüllsubstanzen der bekannten Liposomen und Transferosomen. In diesem Zusammenhang werden sie vor allem aufgrund ihrer bioadhesiven Merkmale im Bereich der Schleimhautapplikationen eingesetzt, wobei sie insbesondere in die Nasen- und Mundhöhlen eingebracht werden.Due to their amphiphilic properties, the phospholipids also serve as coating substances for the known liposomes and transferosomes. In this context, they are used primarily because of their bioadhesive characteristics in the area of mucosal applications, whereby they are particularly introduced into the nasal and oral cavities.
In chemisch modifizierter Form werden Phospholipide aber auch als oberflächenaktive Formulierungshilfsmittel (Surfactants) verwendet.In chemically modified form, however, phospholipids are also used as surface-active formulation aids (surfactants).
Bekannt ist es auch, mittels Ultraschall Visikel herzustellen, die Phospholi- pide als Umhüllung tragen.It is also known to use ultrasound to produce visicles which carry phospholipids as a covering.
Spezielle Granulate mit Lecithinhüllen sind aus der japanischen Anmeldung JP 91 47 043 bekannt, sowie aus EP-A 493 441 . Diese Granulate, die unter anderem Steroide als bioaktive Substanzen enthalten, werden als Futtermittel-Additive eingesetzt.Special granules with lecithin casings are known from Japanese application JP 91 47 043 and from EP-A 493 441. These granules, which contain steroids as bioactive substances, are used as feed additives.
Lyso-Phospholipide werden gemäß WO 87/04347 als Lösungsvermittler für hydrophobe bioaktive Substanzen beschrieben.According to WO 87/04347, lysophospholipids are described as solubilizers for hydrophobic bioactive substances.
In den internationalen Anmeldungen WO 99/1 641 9 und 99/16421 sind lungengängige Darreichungsformen beschrieben, die als Träger für das Phosphatidylcholin organische Halogenverbindungen einsetzen.
Lecithin als bioaktiven Inhaltsstoff enthalten Weichgelatinekapseln, die sich als KALffi Lecithin im Handel befinden und die 1200 mg Sojalecithin enthalten. Um diese Menge Lecithin allerdings in einer Kapsel unterbringen zu können, müssen Kapselgrößen gewählt werden, die sich der Zentimeter- grenze nähern und somit eine eingeschränkte Compliance bedingen.International applications WO 99/1 641 9 and 99/16421 describe respirable dosage forms which use organic halogen compounds as carriers for the phosphatidylcholine. Lecithin as a bioactive ingredient contains soft gelatin capsules, which are commercially available as KAL ffi lecithin and which contain 1200 mg soy lecithin. In order to be able to accommodate this amount of lecithin in a capsule, however, capsule sizes must be selected that approach the centimeter limit and thus result in limited compliance.
Aus dem deutschen Patent DE 199 17 249 ist ein Verfahren zur Herstellung von Phosphatidylserin (PS), also einem Phospholipid, bekannt. In diesem Zusammenhang ist angegeben, dass das so erhaltene PS oder entsprechende PS-Produkte durch Einbetten in einem Hartfett in wässrigen Systemen stabilisiert werden kann. Die dort gemachten Angaben beschränken sich allerdings auf Weichgelatinekapseln, die das spezielle PS im Inhalt aufweisen.A process for the preparation of phosphatidylserine (PS), that is to say a phospholipid, is known from German patent DE 199 17 249. In this connection it is stated that the PS or corresponding PS products obtained in this way can be stabilized by embedding them in hard fat in aqueous systems. However, the information given there is limited to soft gelatin capsules, which have the special PS in their content.
Für die vorliegende Erfindung hat sich deshalb aus dem Stand der Technik die Aufgabe gestellt, eine physiologisch verträgliche, Phospholipid-haltige stabile und feste Matrix bestehend aus einem Trägermaterial und einer bioaktiven Komponente bereitzustellen, die zum einen die Phospholipid- Anteile bezogen auf das Ausgangsmaterial in Anteilen enthält, die über die bekannten Mengen hinausgehen, in denen Phospholipide als Umhüllung oder Formulierungs-Hilfsmittel eingesetzt werden, und die somit Phospholi- pid-Mengen enthalten, die beispielsweise der Nahrungsergänzung dienen können. Zum anderen soll die Matrix aber eine Größe aufweisen, die eine leichte und angenehme Einnahme erlaubt, die aber gleichzeitig ausreicht, eine für eine physiologische Wirkung ausreichende Phospholipid-Menge aufzunehmen.For the present invention, the object of the prior art is therefore to provide a physiologically compatible, phospholipid-containing stable and solid matrix consisting of a carrier material and a bioactive component which, on the one hand, has the proportions of the phospholipid based on the starting material contains that go beyond the known amounts in which phospholipids are used as a coating or formulation aid, and thus contain amounts of phospholipid that can be used, for example, as a food supplement. On the other hand, the matrix should have a size that allows easy and pleasant intake, but at the same time is sufficient to take up an amount of phospholipid sufficient for a physiological effect.
Gelöst wurde diese Aufgabe mit einer entsprechenden Matrix, die einen Gesamtdurchmesser zwischen 0,1 und 5000 μm aufweist und die als bioaktive Komponente > 5 Gew.-%, vorzugsweise > 10 Gew.-% und insbesondere > 20 Gew.-% bezogen auf das Ausgangsmaterial an Aceton- unlöslichen Phospholipid-Bestandteilen enthält.
Überraschend hat sich mit dieser erfindungsgemäßen Matrix gezeigt, dass die Compliance entsprechend der Aufgabenstellung deutlich gesteigert werden kann, da die geringe Matrixgröße die Einnahme erleichtert und dabei vor allem das Schluckgefühl nicht negativ beeinflusst. Außerdem können in der Matrix gemäß Erfindung Phospholipid-Mengen mit bioaktiver Wirkung untergebracht werden, die eine bessere Dosierung der Tagesmenge erlauben. Nicht zu erwarten war auch eine signifikant erhöhte Stabilität der Matrix und vor allem der Phospholipid-Komponente gegenüber destruktiven Einflüssen wie Feuchtigkeit, Licht und Temperatur, also all- gemein oxidativen und/oder hydrolytischen Einwirkungen. Des Weiteren ist eine merklich gesteigerte Bioverfügbarkeit der mit der erfindungsgemäßen Matrix verabreichten Phospholipide festzustellen. Schließlich bietet die Matrix den Vorteil, dass sie in Abhängigkeit vom jeweiligen Herstellungsverfahren und im Hinblick auf die Optik, Haptik und den Geschmack in zahlreichen Varianten hergestellt werden kann. Diese Vorteile waren so nicht vorherzusehen.This object was achieved with a corresponding matrix which has a total diameter between 0.1 and 5000 μm and which, as a bioactive component, is> 5% by weight, preferably> 10% by weight and in particular> 20% by weight, based on the Contains starting material of acetone-insoluble phospholipid components. Surprisingly, it has been shown with this matrix according to the invention that compliance can be significantly increased in accordance with the task, since the small matrix size makes it easier to take and above all does not negatively influence the feeling of swallowing. In addition, amounts of phospholipid with bioactive activity can be accommodated in the matrix according to the invention, which allow a better dosage of the daily amount. A significantly increased stability of the matrix and especially the phospholipid component against destructive influences such as moisture, light and temperature, that is to say generally oxidative and / or hydrolytic effects, was also not to be expected. Furthermore, there is a noticeably increased bioavailability of the phospholipids administered with the matrix according to the invention. Finally, the matrix offers the advantage that it can be produced in numerous variants depending on the respective manufacturing process and with regard to the look, feel and taste. These advantages could not have been foreseen.
Der Ausdruck "Matrix" ist gemäß vorliegender Erfindung definiert als Gesamtheit aus Trägermaterial und bioaktiver Komponente, wobei die bio- aktive Komponente im Trägermaterial homogen oder heterogen verteilt sein kann oder das Trägermaterial die bioaktive Komponente wenigstens teilweise umhüllen kann; die bioaktive Komponente kann aber auch auf dem Trägermaterial aufgebracht sein. Dabei sind selbstverständlich auch Mischformen dieser Varianten möglich.According to the present invention, the term “matrix” is defined as the entirety of the carrier material and the bioactive component, the bioactive component being distributed homogeneously or heterogeneously in the carrier material or the carrier material being able to at least partially encase the bioactive component; however, the bioactive component can also be applied to the carrier material. Mixed forms of these variants are of course also possible.
Die Bezeichnung "hart" definiert den Aggregatzustand der beanspruchten Matrix im Sinn von nicht weich und umfasst alle damit im Einklang stehenden und von der äußeren Form unabhängigen Zustände wie Pellets, Granulate, Hart-Kapseln usw. Weichgelatine-Kapseln fallen damit ausdrücklich nicht unter diese Definition. Amorphe, plastische Erscheinungsformen von harter Konsistenz, erfüllen jedoch die Bedingungen einer harten Matrix.
Unter dem Begriff "bioaktiv" soll im Folgenden die Wirkung der Phospholipide in der Art verstanden werden, dass sie im lebenden Organismus während oder nach ihrer Freisetzung aus der Kapsel im Resorptionsbereich, auf dem Transportweg oder am Zielort eine biologische Wirkung entfalten, was üblicherweise auf pharmazeutische Präparate im Human- und Veterinärbereich zutrifft.The term "hard" defines the physical state of the claimed matrix in the sense of not being soft and includes all states that are in harmony with it and are independent of the external shape, such as pellets, granules, hard capsules, etc. Soft gelatin capsules therefore expressly fall outside this definition , Amorphous, plastic manifestations of hard consistency, but fulfill the conditions of a hard matrix. In the following, the term “bioactive” is to be understood as meaning the effect of the phospholipids in such a way that they have a biological effect in the living organism during or after their release from the capsule in the absorption area, on the transport route or at the destination, which is usually pharmaceutical Preparations in the human and veterinary field apply.
Entsprechend der vorliegenden Erfindung wird eine Matrix bevorzugt, die zwischen 5 und 90 Gew.-% und insbesondere zwischen 20 und 80 Gew.- % bezogen auf das Ausgangsmaterial an Aceton-unlöslichen Phospholipid- Bestandteilen enthält, wobei Anteile als besonders bevorzugt anzusehen sind, die zwischen 40 und 70 Gew.-% liegen. Phosphatidylserin, -cholin, - ethanolamin, -inosit, -glycerin, deren Lyso-Verbindungen und/oder deren Derivate sind bevorzugte Aceton-unlösliche Bestandteile im Sinne der vorliegenden Erfindung. Diese Verbindungen enthalten neben der Kopfgruppe (also z.B. Serin, Cholin, Inosit etc.) an den Position sn-1 bzw. sn-2 vorzugsweise jeweils einen Rest, der von einer an die Hydroxygruppen des Glycerins gebundenen C2-C30-Carbonsäure, insbesondere einer C12-C28- Carbonsäure stammt. Die Säurereste können linear oder verzweigt, gesät- tigt oder ein- oder mehrfach ungesättigt sein. Besondes bevorzugte Reste sind Reste, die durch die Bindung von Essigsäure, Buttersäure, Capronsäu- re, Caprylsäure, Caprinsäure, Laurinsäure, Myristinsäure, Arachinsäure, Behensäure, Lignocerinsäure, -Linolensäure, Eicosapentaensäure, Eruca- säure, Nervonsaure, a- oder ?-Eleostearinsäure oder Parinarsäure gebildet werden. Besonders bevorzugt sind Reste, die durch Bindung von Palmitin- säure, Stearinsäure, Ölsäure, Linolsäure, α-Linolensäure, Arachidonsäure oder Docosahexaensäure gebildet werden. Die an die beiden noch verfügbaren OH-Gruppen des Glycerins gebundenen Säurereste können dabei gleich oder unterschiedlich sein.According to the present invention, a matrix is preferred which contains between 5 and 90% by weight and in particular between 20 and 80% by weight, based on the starting material, of acetone-insoluble phospholipid constituents, fractions being particularly preferred which are between 40 and 70% by weight. Phosphatidylserine, choline, ethanolamine, inositol, glycerol, their lyso compounds and / or their derivatives are preferred acetone-insoluble constituents for the purposes of the present invention. In addition to the head group (for example, serine, choline, inositol, etc.), these compounds each preferably contain a residue at position sn-1 or sn-2, which is derived from a C 2 -C 30 -carboxylic acid bonded to the hydroxyl groups of glycerol, in particular a C 12 -C 28 carboxylic acid. The acid residues can be linear or branched, saturated or mono- or polyunsaturated. Particularly preferred residues are residues which are caused by the binding of acetic acid, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, arachic acid, behenic acid, lignoceric acid, linolenic acid, eicosapentaenoic acid, erucic acid, nervonic acid, a- or? -Earic acid or parinaric acid are formed. Residues formed by binding palmitic acid, stearic acid, oleic acid, linoleic acid, α-linolenic acid, arachidonic acid or docosahexaenoic acid are particularly preferred. The acid residues bound to the two OH groups of the glycerol still available can be the same or different.
Des Weiteren haben sich insbesondere Sphingophospholipide und hieraus bevorzugt das Sphingomyelin und deren Derivate geeignet gezeigt.
Als "hartes" Trägermaterial haben sich (un-)modifizierte Kohlenhydrate und Proteine, hydrophobe Materialien wie Wachse, Triglyceride, Lipide und Polymere oder mineralische Komponenten wie Silikate und deren Mischungen als besonders geeignet gezeigt. Die Lipide können hydriert sein oder eine spezielle Zusammensetzung aufweisen; bei den Polymeren kann es sich um pharmazeutische und/oder Lebensmittel-geeignete Polymere handeln. Zu erwähnen sind dabei vor allem Getreideprodukte von Mais, Weizen, Hafer, Reis usw., die als Flakes oder Extrudate typische harte Trägermaterialien darstellen.Furthermore, sphingophospholipids in particular, and preferably sphingomyelin and its derivatives, have been found to be suitable. (Un) modified carbohydrates and proteins, hydrophobic materials such as waxes, triglycerides, lipids and polymers or mineral components such as silicates and their mixtures have proven to be particularly suitable as “hard” carrier materials. The lipids can be hydrogenated or have a special composition; the polymers can be pharmaceutical and / or food-grade polymers. Of particular note are cereal products from corn, wheat, oats, rice, etc., which are typical hard carrier materials as flakes or extrudates.
Um den jeweiligen Matrixformen und Anwendungsfällen Rechnung tragen zu können, sieht die Erfindung vor, dass als Vertreter der Kohlenhydrate insbesondere Stärke(-Derivate), Mono- und Disaccharide sowie deren Zuckeralkohole, Glucosesirup, Dextrine und Hydrokolloide, wie z.B. Algina- te, Pektine, Chitosan und Cellulose(-Derivate) eingesetzt werden. Als besonders geeignete Vertreter der Proteine sind pflanzliche, tierische oder mikrobielle Eiweiße, wie z.B. Zein, Gluten, Gelatine, Kaseine, Molkeproteine, sowie Single-cell-Proteine, texturierte Proteine wie versponnenes oder extrudiertes (Soja-)Protein-lsolat oder Mischungen daraus anzusehen.In order to be able to take the respective matrix forms and applications into account, the invention provides that, as representatives of the carbohydrates, in particular starch (derivatives), mono- and disaccharides and their sugar alcohols, glucose syrup, dextrins and hydrocolloids, such as e.g. Algatin, pectins, chitosan and cellulose (derivatives) can be used. Vegetable, animal or microbial proteins, such as e.g. Zein, gluten, gelatin, caseins, whey proteins, as well as single-cell proteins, textured proteins such as spun or extruded (soy) protein isolate or mixtures thereof.
Die jeweiligen speziellen Vertreter können natürlich im Bedarfsfall um andere geeignete Trägermaterialien erweitert werden, wobei insbesondere als Kohlenhydrate Maltodextrine, Saccharose, Mono- und Disaccharide sowie deren Alkohole, modifizierte Stärken (z.B. Ester und Ether), Gum acacia, Xanthangum, Gum Arabicum, Carrageenan, Furcelleran, Agar, Alginate, Tragant und Carboxymethylcellulose zu empfehlen sind.If necessary, the respective special representatives can of course be extended by other suitable carrier materials, in particular as carbohydrates maltodextrins, sucrose, mono- and disaccharides and their alcohols, modified starches (eg esters and ethers), gum acacia, xanthan gum, gum arabic, carrageenan, Furcelleran, agar, alginates, tragacanth and carboxymethyl cellulose are recommended.
An hydrophoben Materialien können ergänzend zu den bevorzugten Vertretern auch hydrierte pflanzliche Öle verwendet werden; aber auch natür- liehe Öle, wie Palmöl, Baumwollsamenöl, Sojabohnenöl, Maisöl, Palmkern- öl, Babassuöl, Sonnenblumenöl und Färberdistelöl können verwendet werden, die auch mit Bienenwachs, Erdöl-basiertem Paraffinwachs, Reis-
kleiewachs, Castorwachs, Cardellita-Wachs, Carnauba-Wachs, Schellack und mikrokristallinem Wachs gemischt sein können.In addition to the preferred representatives, hydrogenated vegetable oils can also be used on hydrophobic materials; but also natural oils, such as palm oil, cottonseed oil, soybean oil, corn oil, palm kernel oil, babassu oil, sunflower oil and safflower oil can also be used, which can also be used with beeswax, petroleum-based paraffin wax, rice bran wax, castor wax, cardellita wax, carnauba wax, shellac and microcrystalline wax can be mixed.
Als weitere Vertreter der Lipide empfehlen sich Tristearine, Stearinsäure und Fette, wobei natürlich dem Stand der Technik entsprechend auch die Phospholipide selbst als Umhüllung oder deren Bestandteil gewählt werden können.Tristearins, stearic acid and fats are recommended as further representatives of the lipids, although the phospholipids themselves can of course also be chosen as the coating or their constituent in accordance with the prior art.
Ebenso breit wie der Anteilsbereich der bioaktiven Komponente, ist der Bereich, den das Trägermaterial abdecken kann. Bewährt haben sich diesbezüglich Anteile von < 95 Gew.-% und insbesondere solche, die zwischen 30 und 80 Gew.-% bezogen auf das Gesamtmatrixgewicht liegen. Bevorzugt ist der Anteil an Trägermaterial in der Matrix von > 5 Gew.-%, insbesondere 10 Gew.-%, mehr bevorzugt > 20 Gew.-%, noch mehr bevorzugt > 40 Gew.-% und am meisten bevorzugt ≥ 50 Gew.-% und bis zu 95 Gew.-%, insbesondere bis zu 90 Gew.-%, mehr bevorzugt bis zu 70 Gew.-% und noch mehr bevorzugt bis zu 60 Gew.-%. Auf diese Weise können die Mengen an Inhaltsstoff genau auf die Art des Trägermaterials bzw. auf den jeweiligen Anwendungszweck abgestimmt werden.The range that the carrier material can cover is just as wide as the proportion of the bioactive component. Proportions of <95% by weight and in particular those between 30 and 80% by weight, based on the total matrix weight, have proven useful in this regard. The proportion of carrier material in the matrix is preferably> 5% by weight, in particular 10% by weight, more preferably> 20% by weight, even more preferably> 40% by weight and most preferably ≥ 50% by weight. % and up to 95% by weight, in particular up to 90% by weight, more preferably up to 70% by weight and even more preferably up to 60% by weight. In this way, the amounts of ingredient can be matched exactly to the type of carrier material or to the particular application.
Im Vordergrund der vorliegenden Erfindung steht zwar die stabile und harte Matrix, die als bioaktive Komponente zumeist überwiegend Phospholipide enthält, doch kann die Matrix selbstverständlich auch weitere bioaktive Substanzen, wie Aminosäuren, Vitamine, Polyphenole, Kohlenhydrate, Lipide, Spurenelemente und Mineralstoffe und deren geeignete Derivate enthalten. Hier kommen vor allem die essenziellen Aminosäuren in Frage, aber auch beispielsweise Kreatin und andere spezielle Aminosäuren wie z.B. Theanin und ihre Derivate; als Vertreter der Vitamine bieten sich vor allem die fettlöslichen an, wie die Vitamin E-Familie, die Tocotrienole, Phytosterine und andere bioaktive Fettbegleitstoffe, sowie von den Phos- pholipiden abweichende Vertreter der Vitamin D-Reihe oder Vitamin C. Ebenfalls geeignet haben sich auch typische Fischöl-Lipide gezeigt, wie Docosahexaen-
und Eicosahexaen-Säure oder allgemein Omega-3-Fettsäuren in Triglycerid- Form, aber auch konjugierte Linolensäure. Diese weiteren bioaktiven Substanzen können dem Trägermaterial, der bioaktiven Komponente oder auch beiden zugesetzt werden.Although the focus of the present invention is on the stable and hard matrix, which mostly contains phospholipids as the bioactive component, the matrix can of course also contain other bioactive substances such as amino acids, vitamins, polyphenols, carbohydrates, lipids, trace elements and minerals and their suitable derivatives contain. Above all, the essential amino acids come into question, but also, for example, creatine and other special amino acids such as theanine and their derivatives; The representatives of the vitamins are primarily the fat-soluble ones, such as the vitamin E family, the tocotrienols, phytosterols and other bioactive fat accompanying substances, as well as representatives of the vitamin D series or vitamin C that deviate from the phospholipids. Also suitable are typical fish oil lipids shown how docosahexaen and eicosahexaenic acid or generally omega-3 fatty acids in triglyceride form, but also conjugated linolenic acid. These further bioactive substances can be added to the carrier material, the bioactive component or both.
Besonders geeignet als Trägermaterialien sind erfindungsgemäß Stoffe, welche die Ausprägung einer vollständigen Verkapselung ermöglichen sowie Stoffe, welche eine Matrix mit hoher Stabilität und niedriger Scherbeanspruchung bereitstellen.According to the invention, particularly suitable as carrier materials are substances which enable complete encapsulation to be achieved, and substances which provide a matrix with high stability and low shear stress.
Erfindungswesentlich ist für die beanspruchte Matrix unter anderem deren spezieller Durchmesser, der sie neben ihrem harten Zustand unter anderem von den bekannten größeren Weichgelatinekapseln unterscheidet.Essential to the invention for the claimed matrix is, among other things, its special diameter, which, in addition to its hard state, distinguishes it, among other things, from the known larger soft gelatin capsules.
Innerhalb des beanspruchten breiten Spektrums sind Durchmesser der Gesamtmatrix als bevorzugt anzusehen, die zwischen 10 μm und 1000 tm und insbesondere zwischen 50 und 500 μm liegen.Within the claimed broad spectrum, diameters of the total matrix that lie between 10 μm and 1000 μm and in particular between 50 and 500 μm are to be regarded as preferred.
Die beanspruchte Matrix ist wie schon erwähnt nicht auf eine spezielle Form beschränkt und sie kann demzufolge sphärisch, rundlich oder unregelmäßig geformt sein. Als besonders geeignet haben sich allerdings kugelige oder linsenförmige Ausprägungsformen gezeigt, wobei natürlich auch alle anderen Formvarianten, wie Zylinder, Kissen, amorphe Zustände (z.B. Flakes) und ähnliches, je nach Anwendung in Frage kommen können, immer natürlich bestehend aus dem Trägermaterial und der bioaktiven Komponente.As already mentioned, the claimed matrix is not restricted to a special shape and, consequently, it can be spherical, rounded or irregular in shape. However, spherical or lenticular forms have been shown to be particularly suitable, although of course all other shape variants, such as cylinders, pillows, amorphous states (e.g. flakes) and the like, depending on the application, can of course always consist of the carrier material and the bioactive one Component.
Schließlich sieht die Erfindung bezüglich des Matrix-Inhalts vorzugsweise vor, dass dieser von flüssiger Konsistenz ist, was dann natürlich eine in der Regel starre und harte Umhüllung notwendig macht.
Als besonders gut geeignet gezeigt haben sich Matrix-Varianten in Form einer Mikrokapsel, was die vorliegende Erfindung ebenfalls berücksichtigt.Finally, the invention preferably provides for the matrix content to have a liquid consistency, which of course then necessitates a generally rigid and hard coating. Matrix variants in the form of a microcapsule have been shown to be particularly suitable, which the present invention also takes into account.
Neben der eigentlichen Matrix beansprucht die vorliegende Erfindung auch deren Verwendung in Funktionsnahrungsmitteln (Functional Food), Spezial- nahrungsmitteln (Special Food) und Nahrungsergänzungsmittel (Dietary Supplements), wobei insbesondere die verzögerte Freisetzung der bioaktiven Komponente im Vordergrund steht. Die Retardwirkung schließt allerdings nicht aus, dass die komplette Matrix oder deren Bestandteile (Träger- material, bioaktive Komponente) von den Magensäften angegriffen werden können oder dass sie im Gl-Trakt chemischen und/oder enzymatischen Einflüssen unterliegen. Als bevorzugter Verwendungszweck für die beanspruchte Matrix ist die Vorbeugung erhöhter Serumcholesterin-Spiegel und (a-)typischer Diabetes-Symptome sowie die Stärkung der mentalen Fitness, der körperlichen Belastbarkeit und der körperlichen und geistigen Leistungsfähigkeit vorgesehen.In addition to the actual matrix, the present invention also claims its use in functional foods, special foods and dietary supplements, with particular emphasis on the delayed release of the bioactive component. However, the sustained release effect does not exclude that the complete matrix or its components (carrier material, bioactive component) can be attacked by the gastric juices or that they are subject to chemical and / or enzymatic influences in the GI tract. The preferred use for the claimed matrix is to prevent increased serum cholesterol levels and (a) typical diabetes symptoms, as well as to strengthen mental fitness, physical resilience and physical and mental performance.
Für die Herstellung der erfindungsgemäßen Matrix kommen alle geeigneten Verfahren des Standes der Technik und deren ähnliche oder abgeleitete Methoden in Frage, was die Vorteilhaftigkeit der Erfindung zusätzlich unterstreicht.All suitable methods of the prior art and their similar or derived methods can be used for the production of the matrix according to the invention, which further underlines the advantage of the invention.
Die beanspruchte Matrix stellt aufgrund ihrer speziellen, möglichen Merkmale, wie beispielsweise Durchmesser, Umhüllung und Kapselkern, eine besonders geeignete Darreichungsform dar, da sie in zahlreichen Erscheinungsund Geschmacksformen herstellbar ist und deshalb festen, halbfesten und flüssigen Nahrungsmitteln ohne Probleme und bei hoher Eigenstabilität zugesetzt werden kann.Due to its special, possible characteristics such as diameter, coating and capsule core, the claimed matrix represents a particularly suitable dosage form, since it can be produced in numerous forms and flavors and can therefore be added to solid, semi-solid and liquid foods without problems and with high inherent stability ,
Selbstverständlich ist als geeignetste Darreichungsform die direkte orale Einnahme anzusehen.
Die nachfolgenden Beispiele unterstreichen die Vorteile der physiologisch verträglichen Phospholipid-haltigen, stabilen und harten Matrix gemäß Erfindung.Of course, the most suitable dosage form is direct oral intake. The following examples underline the advantages of the physiologically compatible phospholipid-containing, stable and hard matrix according to the invention.
Beispiele Beispiel 1 Mikrokapsel mit 8 Gew.-% PhosphatidylserinExamples Example 1 Microcapsule with 8% by weight phosphatidylserine
Mit Hilfe der bekannten „Sprüh-Technologie" wurde eine 20 Gew.-%-ige Lösung Phosphatidylserin (LeciPS's 20F der Firma Degussa BioActives GmbH), bestehend aus einer Mischung von Triglyceriden, Phospholipiden und Glycolipiden, mit einem natürlichen, pflanzlichen Fett in einer Matrix verkapselt. Das natürliche, pflanzliche Fett war durch folgende Merkmale charakterisiert: Schmelzpunkt ca. 55 °C, Peroxidzahl max. 2 meq O/kg, Säurezahl max. 1 mg KOH/g, lodzahl max. 5 gl/100 g, Verseifungszahl 185-215 mg KOH/g, mehr als 94 % der natürlichen Säuren (ca. 33 % Palmitinsäure, ca. 60 % Stearinsäure) sind gesättigt.With the help of the known “spray technology”, a 20% by weight solution of phosphatidylserine (LeciPS ' s 20F from Degussa BioActives GmbH), consisting of a mixture of triglycerides, phospholipids and glycolipids, with a natural, vegetable fat in The natural, vegetable fat was characterized by the following characteristics: melting point about 55 ° C, peroxide number max. 2 meq O / kg, acid number max. 1 mg KOH / g, iodine number max. 5 gl / 100 g, saponification number 185-215 mg KOH / g, more than 94% of the natural acids (approx. 33% palmitic acid, approx. 60% stearic acid) are saturated.
Die so erhaltene kugelförmige Matrix in Form von Mikrokapseln wies einen durchschnittlichen Gesamtdurchmesser von 100 bis 250 //m und folgende inhaltliche Zusammensetzung auf:The spherical matrix obtained in this way in the form of microcapsules had an average overall diameter of 100 to 250 // m and the following composition:
8 Gew.-% Phosphatidylserin, 55 Gew.-% pflanzliches Fett und 37 Gew.-% einer Mischung aus Triglyceriden, Glycolipiden und weiteren Phospholipi- den.8% by weight of phosphatidylserine, 55% by weight of vegetable fat and 37% by weight of a mixture of triglycerides, glycolipids and other phospholipids.
Stabilität der Phospholipide:Stability of the phospholipids:
Die Tabelle 1 zeigt für das sehr hydrolyseempfindliche Phosphatidylserin, dass das Einbetten der Phospholipide in der erfindungsgemäßen Matrix unter anderem einen stabilisierenden Effekt gegenüber Hydrolyse bewirkt.Table 1 shows for the very hydrolysis-sensitive phosphatidylserine that embedding the phospholipids in the matrix according to the invention effects, among other things, a stabilizing effect against hydrolysis.
Beispiel 2Example 2
Mikrokapsel mit 14 Gew.-% Phosphatidylcholin
Mit Hilfe der bekannten „Sprüh-Technologie" wurde eine 35 Gew.-%-ige Lösung von Phosphatidylcholin (Epikuron® 1 35F der Firma Degussa BioActives GmbH), bestehend aus einer Mischung von Triglyceriden, Phos- pholipiden und Glycolipiden, mit einem natürlichen, pflanzlichen Fett ver- kapselt. Das natürliche, pflanzliche Fett war durch folgende Merkmale charakterisiert:Microcapsule with 14% by weight phosphatidylcholine Using the known "spray technology", a 35% by weight solution of phosphatidylcholine (Epikuron ® 1 35F from Degussa BioActives GmbH) consisting of a mixture of triglycerides, phospholipids and glycolipids with a natural, encapsulated vegetable fat The natural, vegetable fat was characterized by the following features:
Schmelzpunkt ca. 55 °C, Peroxidzahl max. 2 meq O/kg, Säurezahl max. 1 mg KOH/g, lodzahl max. 5 gl/1 00 g, Verseifungszahl 1 85-21 5 mg KOH/g, mehr als 94 % der natürlichen Säuren (ca. 33 % Palmitinsäure, ca. 60 % Stearinsäure) sind gesättigt.Melting point approx. 55 ° C, peroxide number max. 2 meq O / kg, acid number max. 1 mg KOH / g, iodine number max. 5 gl / 100 g, saponification number 1 85-21 5 mg KOH / g, more than 94% of the natural acids (approx. 33% palmitic acid, approx. 60% stearic acid) are saturated.
Die so erhaltene kugelförmige Matrix in Form von Mikrokapseln wies einen durchschnittlichen Gesamtdurchmesser von 1 00 bis 250 μm und folgende inhaltliche Zusammensetzung auf: 14 Gew.-% Phosphatidylcholin, 46 Gew.-% pflanzliches Fett und 40 Gew.-The spherical matrix thus obtained in the form of microcapsules had an average overall diameter of 1 00 to 250 μm and the following composition: 14% by weight phosphatidylcholine, 46% by weight vegetable fat and 40% by weight
% einer Mischung aus Triglyceriden, Glycolipiden und weiteren Phospho- lipiden.% of a mixture of triglycerides, glycolipids and other phospholipids.
Stabilität der Phospholipide:Stability of the phospholipids:
Die Tabelle 1 zeigt für das sehr hydrolyseempfindliche Phosphatidylcholin, dass das Einbetten der Phospholipide in der erfindungsgemäßen Matrix unter anderem einen stabilisierenden Effekt gegenüber Hydrolyse bewirkt.For the very hydrolysis-sensitive phosphatidylcholine, Table 1 shows that embedding the phospholipids in the matrix according to the invention has, inter alia, a stabilizing effect against hydrolysis.
Beispiel 3Example 3
Mikrokapsel mit 50 Gew.-% PhosphatidylserinMicrocapsule with 50% by weight phosphatidylserine
Mit Hilfe der bekannten „Fluid-Bed-Technologie" wurde ein 90 Gew.-%-iges Phosphatidylserin-Pulver in Form eines aus Sojabohnen angereichten Lecithins (LeciPS® 90PN der Firma Degussa BioActives GmbH), mit einem natürlichen, pflanzlichen Fett in einer Matrix verkapselt. Das natürliche, pflanzliche Fett war durch folgendende Merkmale charakterisiert:With the aid of the known "fluid bed technology", a 90 wt .-% - sodium phosphatidylserine powder in the form of an attached ranged from soybean lecithin (LeciPS ® 90PN Degussa BioActives GmbH), with a natural vegetable fat in a matrix The natural, vegetable fat was characterized by the following characteristics:
Schmelzpunkt ca. 55 °C, Peroxidzahl max. 2 meq 0/kg, Säurezahl max. 1 mg KOH/g, lodzahl max. 5 gl/100 g, Verseifungszahl 185-215 mg KOH/g,
mehr als 94 % der natürlichen Säuren (ca. 33 % Palmitinsäure, ca. 60 % Stearinsäure) sind gesättigt.Melting point approx. 55 ° C, peroxide number max. 2 meq 0 / kg, acid number max. 1 mg KOH / g, iodine number max. 5 gl / 100 g, saponification number 185-215 mg KOH / g, more than 94% of the natural acids (approx. 33% palmitic acid, approx. 60% stearic acid) are saturated.
Die so erhaltene kugelförmige Matrix in Form von Mikrokapseln wies einen durchschnittlichen Gesamtdurchmesser von 1 00 bis 250 μm und folgende inhaltliche Zusammensetzung auf:The spherical matrix thus obtained in the form of microcapsules had an average overall diameter of 1 00 to 250 μm and the following composition:
5 Gew.-% Phosphatidylserin, 45 Gew.-% pflanzliches Fett und 5 Gew.-% weiterer Phospholipide. Stabilität der Phospholipide: Die Tabelle 1 zeigt für das sehr hydrolyseempfindliche Phosphatidylserin, dass das Einbetten der Phospholipide in der erfindungsgemäßen Matrix unter anderem einen stabilisierenden Effekt gegenüber Hydrolyse bewirkt.5% by weight of phosphatidylserine, 45% by weight of vegetable fat and 5% by weight of further phospholipids. Stability of the phospholipids: For the very hydrolysis-sensitive phosphatidylserine, Table 1 shows that embedding the phospholipids in the matrix according to the invention has, inter alia, a stabilizing effect against hydrolysis.
Tabelle 1Table 1
Als Vergleich diente das jeweilige phospholipidhaltige Lecithin (Beispiele 1 und 3: Phosphatidylserin; Beispiel 2: Phosphatidylcholin), das ohne Matrix in wässriger Lösung (pH 3,5; T = 4 °C) gelagert wurde.The respective phospholipid-containing lecithin (Examples 1 and 3: phosphatidylserine; Example 2: phosphatidylcholine), which was stored without a matrix in aqueous solution (pH 3.5; T = 4 ° C.), served as a comparison.
Die Erfindungsbeispiele wurden mit phospholipidhaltigen Mikrokapseln (Beispiele 1 und 3: Phosphatidylserin; Beispiel 2: Phosphatidylcholin) durchgeführt, wobei die Mikrokapseln als Beispiel für ein typisches Functional Food in einem sauren Fruchtsaft (pH 3,5; T = 4 °C) gelagert wurden.
The inventive examples were carried out using phospholipid-containing microcapsules (Examples 1 and 3: phosphatidylserine; Example 2: phosphatidylcholine), the microcapsules being stored as an example of a typical functional food in an acidic fruit juice (pH 3.5; T = 4 ° C.).
Claims
AnsprücheExpectations
Physiologisch verträgliche, Phospholipid-haltige, stabile und harte Matrix bestehend aus einem Trägermaterial und einer bioaktiven Komponente, dadurch gekennzeichnet, dass die Gesamtmatrix einen Gesamtdurchmesser zwischen 0, 1 und 5000 μm aufweist und dass sie als bioaktive Komponente 5 Gew.-%, bezogen auf das Ausgangsmaterial an Aceton-unlöslichen Phospholipid-Bestandteilen enthält.Physiologically compatible, phospholipid-containing, stable and hard matrix consisting of a carrier material and a bioactive component, characterized in that the total matrix has a total diameter between 0, 1 and 5000 μm and that it is 5% by weight, based on the bioactive component contains the starting material of acetone-insoluble phospholipid constituents.
2. Matrix nach Anspruch 1 , dadurch gekennzeichnet, dass sie zwischen 5 und 90 Gew.-%, insbesondere zwischen 20 und 80 Gew.- % und besonders bevorzugt zwischen 40 und 70 Gew.-%, jeweils bezogen auf das Ausgangsmaterial, an Aceton-unlöslichen Phospho- lipid-Bestandteilen enthält.2. Matrix according to claim 1, characterized in that it contains between 5 and 90% by weight, in particular between 20 and 80% by weight and particularly preferably between 40 and 70% by weight, in each case based on the starting material, of acetone contains insoluble phospholipid constituents.
3. Matrix nach einem der Ansprüche 1 oder 2, dadurch gekennzeichnet, dass sie als Aceton-unlösliche Bestandteile (Lyso-)PhosphatidyΙ- serin, -cholin, -ethanolamin, -inosit, -glycerin und/oder deren Deriva- te, und/oder Sphingophospholipide, insbesondere Sphingomyelin, enthält.3. Matrix according to one of claims 1 or 2, characterized in that it contains as acetone-insoluble constituents (lyso) phosphatidyΙ serine, choline, ethanolamine, inositol, glycerol and / or their derivatives, and / or sphingophospholipids, especially sphingomyelin.
4. Matrix nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, dass das Trägermaterial (un-)modifizierte Kohlenhydrate und Protei- ne, hydrophobe Materialien wie Wachse, Triglyceride, Lipide und4. Matrix according to one of claims 1 to 3, characterized in that the carrier material (un-) modified carbohydrates and proteins, hydrophobic materials such as waxes, triglycerides, lipids and
Polymere oder mineralische Komponenten wie Silikate und deren Mischungen enthält.Contains polymers or mineral components such as silicates and their mixtures.
5. Matrix nach Anspruch 4, dadurch gekennzeichnet, dass es sich bei den Kohlenhydraten um Stärke(-Derivate), Mono- und Disaccharide sowie deren Zuckeralkohole, Glucosesirup, Dextrine und Hydrokolloi- de, wie z.B. Alginate, Pektine, Chitosan, und Cellulose(-Derivate) handelt.5. Matrix according to claim 4, characterized in that the carbohydrates are starch (derivatives), mono- and disaccharides and their sugar alcohols, glucose syrup, dextrins and hydrocolloids. de, such as alginates, pectins, chitosan, and cellulose (derivatives).
6. Matrix nach einem der Ansprüche 4 oder 5, dadurch gekennzeich- net, dass es sich bei den Proteinen um pflanzliche, tierische oder mikrobielle Eiweiße, wie z.B. Zein, Gluten, Gelatine, Kaseine, Molkeproteine, Sojaprotein, sowie Single-cell-Proteine, texturierte Proteine oder Mischungen daraus handelt.6. Matrix according to one of claims 4 or 5, characterized in that the proteins are vegetable, animal or microbial proteins, such as e.g. Zein, gluten, gelatin, caseins, whey proteins, soy protein, as well as single-cell proteins, textured proteins or mixtures thereof.
7. Matrix nach einem der Ansprüche 1 bis 6, dadurch gekennzeichnet, dass das Trägermaterial einen Anteil von ≤ 95 Gew.-% und insbesondere zwischen 30 und 80 Gew.-% bezogen auf das Gesamtmatrixgewicht ausmacht.7. Matrix according to one of claims 1 to 6, characterized in that the carrier material makes up a proportion of ≤ 95 wt .-% and in particular between 30 and 80 wt .-% based on the total matrix weight.
8. Matrix nach einem der Ansprüche 1 bis 7, dadurch gekennzeichnet, dass sie weitere bioaktive Substanzen, wie Aminosäuren, Vitamine, Polyphenole, Kohlenhydrate, Lipide, Spurenelemente, Mineralstoffe und deren geeignete Derivate enthält.8. Matrix according to one of claims 1 to 7, characterized in that it contains further bioactive substances, such as amino acids, vitamins, polyphenols, carbohydrates, lipids, trace elements, minerals and their suitable derivatives.
9. Matrix nach einem der Ansprüche 1 bis 8, dadurch gekennzeichnet, dass die Gesamtmatrix einen Durchmesser zwischen 10 μm und 1000 μm und insbesondere zwischen 50 bis 500 μm, aufweist.9. Matrix according to one of claims 1 to 8, characterized in that the total matrix has a diameter between 10 microns and 1000 microns and in particular between 50 to 500 microns.
10. Matrix nach einem der Ansprüche 1 bis 9, dadurch gekennzeichnet, dass sie kugelig oder linsenförmig ist.10. Matrix according to one of claims 1 to 9, characterized in that it is spherical or lenticular.
1 1 . 'Matrix nach einem der Ansprüche 1 bis 10, dadurch gekennzeichnet, dass sie einen flüssigen Inhalt aufweist.1 1. 'Matrix according to one of claims 1 to 10, characterized in that it has a liquid content.
12. Matrix nach einem der Ansprüche 1 bis 1 1 , dadurch gekennzeichnet, dass sie in Form einer Mikrokapsel vorliegt. 12. Matrix according to one of claims 1 to 1 1, characterized in that it is in the form of a microcapsule.
13. Verwendung der Matrix nach einem der Ansprüche 1 bis 12 in Funktionsnahrungsmitteln (Functional Food), Spezialnahrungsmitteln (Special Food) und Nahrungsergänzungsmitteln (Dietary Supplements), insbesondere mit verzögerter Freisetzung.13. Use of the matrix according to one of claims 1 to 12 in functional foods, special foods and dietary supplements, in particular with delayed release.
14. Verwendung nach Anspruch 13, dadurch gekennzeichnet, dass die Matrix zur Vorbeugung von erhöhten Serumcholesterin-Spiegeln und Diabetes-Symptomen, zur Stärkung der mentalen Fitness, der körperlichen Belastbarkeit und Leistungsfähigkeit eingesetzt wird. 14. Use according to claim 13, characterized in that the matrix is used for the prevention of elevated serum cholesterol levels and diabetes symptoms, for strengthening mental fitness, physical resilience and performance.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10217555A DE10217555A1 (en) | 2002-04-19 | 2002-04-19 | Physiologically compatible, phospholipid-containing, stable and hard matrix |
DE10217555 | 2002-04-19 | ||
PCT/EP2003/004031 WO2003088761A2 (en) | 2002-04-19 | 2003-04-17 | Physiologically compatible, phospholipid-containing, stable and hard matrix |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1499204A2 true EP1499204A2 (en) | 2005-01-26 |
Family
ID=29224601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03718771A Withdrawn EP1499204A2 (en) | 2002-04-19 | 2003-04-17 | Physiologically compatible, phospholipid-containing, stable and hard matrix |
Country Status (6)
Country | Link |
---|---|
US (1) | US20050220857A1 (en) |
EP (1) | EP1499204A2 (en) |
JP (1) | JP2005527207A (en) |
AU (1) | AU2003222823A1 (en) |
DE (1) | DE10217555A1 (en) |
WO (1) | WO2003088761A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2325260T3 (en) | 2003-01-20 | 2009-08-31 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | USE OF SPHINGOLIPIDS TO REDUCE THE LEVELS OF TRIACILGLYCEROL AND CHOLESTEROL IN PLASMA. |
NL1022443C2 (en) | 2003-01-20 | 2004-07-22 | Tno | Sphingolipids for improving the composition of the intestinal flora. |
DE102004038442A1 (en) * | 2004-08-07 | 2006-03-16 | Bioghurt Biogarde Gmbh & Co. Kg | Process for the preparation of non-adhesive phospholipid granules |
JP2008521888A (en) | 2004-11-30 | 2008-06-26 | ネーデルランドセ オルガニサティエ フォール トエゲパストナトールヴェテンシャッペリク オンデルゾエク ティエヌオー | Sphingolipids in the treatment and prevention of steatosis or hepatotoxicity and its sequelae |
ITPD20050164A1 (en) | 2005-05-30 | 2006-11-30 | Fidia Farmaceutici | PROCESS FOR PREPARATION AND ISOLATION OF PHOSPHATIDES |
CA2613803A1 (en) * | 2005-06-28 | 2007-01-04 | Kgk Synergize Inc. | Compositions to improve the bioavailability of polymethoxyflavones and tocotrienols for treatment of cardiovascular disease |
US8877239B2 (en) * | 2010-08-12 | 2014-11-04 | Nutritional Therapeutics, Inc. | Lipid supplements for maintaining health and treatment of acute and chronic disorders |
US9468668B2 (en) | 2011-08-11 | 2016-10-18 | Allergy Research Group, Llc | Flavored chewable lipid supplements for maintaining health and the treatment of acute and chronic disorders |
US9095507B2 (en) | 2011-08-11 | 2015-08-04 | Allergy Research Group, Llc | Chewable wafers containing lipid supplements for maintaining health and the treatment of acute and chronic disorders |
EP2172117B1 (en) | 2008-09-25 | 2011-11-16 | Nestec S.A. | Reducing astringency in compositions containing phenolic compounds |
PT2387391T (en) * | 2009-07-24 | 2017-04-20 | Mika Pharma Ges Für Die Entw Und Vermarktung Pharmazeutischer Produkte Mbh | Method for developing a liquid composition to be applied to the skin as a foam and a composition that can be applied topically |
CN102946866A (en) * | 2010-05-14 | 2013-02-27 | 阿彻丹尼尔斯米德兰德公司 | Food compositions comprising organogels |
US11253531B2 (en) | 2011-08-11 | 2022-02-22 | Nutritional Therapeutics, Inc. | Lipid supplements for reducing nerve action potentials |
US10117885B2 (en) | 2011-08-11 | 2018-11-06 | Allergy Research Group, Llc | Chewable lipid supplements for treating pain and fibromyalgia |
WO2016012861A1 (en) | 2014-07-25 | 2016-01-28 | Enzymotec Ltd. | Nutritional compositions containing phosphatidylserine powder |
CN109568292A (en) * | 2018-12-29 | 2019-04-05 | 中山百灵生物技术有限公司 | A kind of microgel and preparation method thereof containing GPC |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001084961A2 (en) * | 2000-05-08 | 2001-11-15 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4374082A (en) * | 1981-08-18 | 1983-02-15 | Richard Hochschild | Method for making a pharmaceutical and/or nutritional dosage form |
GB8331808D0 (en) * | 1983-11-29 | 1984-01-04 | Unilever Plc | Food product |
EP0185442A3 (en) * | 1984-10-05 | 1988-08-31 | Warner-Lambert Company | A novel sweetener delivery system and a chewing gum composition comprising the sweetener delivery system |
GB8616041D0 (en) * | 1986-07-01 | 1986-08-06 | Unilever Plc | Phosphatide-containing compositions |
US5171737A (en) * | 1989-03-03 | 1992-12-15 | The Liposome Company, Inc. | Emulsions |
US6312719B1 (en) * | 1994-03-04 | 2001-11-06 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
FR2762993B1 (en) * | 1997-05-06 | 1999-08-13 | Inst Rech Biolog Sa | NEW USE OF PHOSPHOLIPIDS OF ANIMAL ORIGIN IN THERAPEUTICS AND / OR DIETETICS |
CA2343116C (en) * | 1998-09-08 | 2008-11-18 | Biomolecular Products, Inc. | Methods and compositions for increasing intestinal absorption of fats |
JP2000300186A (en) * | 1999-04-19 | 2000-10-31 | Kao Corp | Metabolism improving agent |
JP3195594B2 (en) * | 1999-11-02 | 2001-08-06 | 明治乳業株式会社 | A food composition containing a milk-derived phospholipid. |
IL134701A0 (en) * | 2000-02-23 | 2001-04-30 | J P M E D Ltd | Homogeneous solid matrix containing vegetable proteins |
JP2002226394A (en) * | 2001-02-01 | 2002-08-14 | Meiji Milk Prod Co Ltd | Lipid metabolism improving composition |
ES2227479T3 (en) * | 2001-03-26 | 2005-04-01 | Giventis Gmbh | FOOD INTENDED TO INCREASE COGNITIVE CAPACITY. |
JP2003012520A (en) * | 2001-06-25 | 2003-01-15 | Yaizu Suisankagaku Industry Co Ltd | Antioxidant and food and drink containing the same |
-
2002
- 2002-04-19 DE DE10217555A patent/DE10217555A1/en not_active Withdrawn
-
2003
- 2003-04-17 US US10/511,884 patent/US20050220857A1/en not_active Abandoned
- 2003-04-17 AU AU2003222823A patent/AU2003222823A1/en not_active Abandoned
- 2003-04-17 JP JP2003585518A patent/JP2005527207A/en active Pending
- 2003-04-17 WO PCT/EP2003/004031 patent/WO2003088761A2/en active Application Filing
- 2003-04-17 EP EP03718771A patent/EP1499204A2/en not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001084961A2 (en) * | 2000-05-08 | 2001-11-15 | N.V. Nutricia | Preparation for the prevention and/or treatment of vascular disorders |
Also Published As
Publication number | Publication date |
---|---|
AU2003222823A1 (en) | 2003-11-03 |
DE10217555A1 (en) | 2004-02-19 |
US20050220857A1 (en) | 2005-10-06 |
WO2003088761A2 (en) | 2003-10-30 |
JP2005527207A (en) | 2005-09-15 |
WO2003088761A3 (en) | 2004-06-03 |
AU2003222823A8 (en) | 2003-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1499204A2 (en) | Physiologically compatible, phospholipid-containing, stable and hard matrix | |
DE202011050351U1 (en) | Dietetic products or formulations | |
EP3285749B1 (en) | Gel capsule containing sterol and solubilising agent | |
DE212015000033U1 (en) | Therapeutic astaxanthin and phospholipid composition | |
WO2003088765A2 (en) | Functional foods containing a phospholipid-containing stable matrix | |
EP1660097B1 (en) | Physiologically active composition based on phosphatidylserine | |
EP1659878B1 (en) | Formulation based on phospholipids | |
WO2003088949A2 (en) | Matrix comprising a bioactive component containing phospholipid | |
US20220193018A1 (en) | Omega-3 compositions and methods relating thereto | |
WO2004057979A2 (en) | Dietary foodstuff for positively influencing cardiovascular health containing a carob product and an omega-3 fatty acid | |
AU2020260090A1 (en) | Novel hemp and PEA formulation and its use | |
EP3042648B1 (en) | Direct granulate with retarded agent | |
DE10250727B4 (en) | Matrix with a bioactive phospholipid-containing component | |
KR20230104113A (en) | Carotenoid formulations with improved bioavailability | |
MICRO | LEKSHMI RG KUMAR, MF Sc.(PHT-PA3-02) | |
Hadian | Electronic Physician (ISSN: 2008-5842) http://www. ephysician. ir | |
DE10214999A1 (en) | Food or animal food enriched with additives encapsulated in a liposome solution then admixed with wheat flour and extruded to a chilled mill for grinding | |
DE102013021695A1 (en) | Microcapsule with health promoting effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20041014 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
17Q | First examination report despatched |
Effective date: 20080702 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20131101 |